Ruscica, M, Penson, PE, Ferri, N, Sirtori, CR, Pirro, M, Mancini, GBJ, Sattar, N, Toth, PP, Sahebkar, A, Lavie, CJ, Wong, ND and Banach, M (2021) Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP). Progress in Cardiovascular Diseases. ISSN 0033-0620

Preview

Text Nutraceuticals and inflammation.pdf - Accepted Version Available under License Creative Commons Attribution. Download (696kB) | Preview

Abstract

Inflammation is a marker of arterial disease stemming from cholesterol-dependent to -independent molecular mechanisms. In recent years, the role of inflammation in atherogenesis has been underpinned by pharmacological approaches targeting systemic inflammation that have led to a significant reduction in cardiovascular disease (CVD) risk. Although the use of nutraceuticals to prevent CVD has largely focused on lipid-lowering (e.g, red-yeast rice and omega-3 fatty acids), there is growing interest and need, especially now in the time of coronavirus pandemic, in the use of nutraceuticals to reduce inflammatory markers, and potentially the inflammatory CVD burden, however, there is still not enough evidence to confirm this. Indeed, diet is an important lifestyle determinant of health and can influence both systemic and vascular inflammation, to varying extents, according to the individual nutraceutical constituents. Thus, the aim of this Position Paper is to provide the first attempt at recommendations on the use of nutraceuticals with effective anti-inflammatory properties.

Item Type:	Article
Uncontrolled Keywords:	1102 Cardiorespiratory Medicine and Haematology
Subjects:	R Medicine > RM Therapeutics. Pharmacology
Divisions:	Pharmacy & Biomolecular Sciences
Publisher:	Elsevier
Date Deposited:	05 Jul 2021 11:31
Last Modified:	04 Sep 2021 05:17
DOI or ID number:	10.1016/j.pcad.2021.06.010
URI:	https://researchonline.ljmu.ac.uk/id/eprint/15218

View Item